"Pharus Diagnostics...announced a global exclusive license agreement with City of Hope cancer center for proprietary biomarkers to be used in early screening of individuals at risk for pancreatic ductal adenocarcinoma (PDAC). This license agreement marks a pivotal step with PharusDx to develop and commercialize a version of its OncoSweep™ liquid biopsy screening for the early detection of PDAC. OncoSweep™ aims to improve on the current standard for early diagnosis of PDAC, offering a non-invasive solution that has been shown in laboratory studies to be highly accurate."